OFER-TRABEC Archivos

Distribución de ofertas de Empleo y Becas.

OFER-TRABEC@LISTSERV.REDIRIS.ES

Opciones: Vista Forum

Use Monospaced Font
Por defecto enseñar Text Part
Mostrar todas las cabeceras de correo

Mensaje: [<< Primero] [< Prev] [Siguiente >] [Último >>]
Tema: [<< Primero] [< Prev] [Siguiente >] [Último >>]
Autor: [<< Primero] [< Prev] [Siguiente >] [Último >>]

Print Responder
Subject:
Emisor:
Servicio de Listas de RedIRIS <[log in para visualizar]>
Reply To:
Servicio de Listas de RedIRIS <[log in para visualizar]>
Fecha:
Thu, 6 Feb 2025 23:07:26 +0100
Content-Type:
text/plain
Parts/Attachments:
text/plain (62 lines)
===
Para darse de ALTA/BAJA del Boletin OFER-TRABEC utilice el siguiente enlace o pongase en contacto con [log in para visualizar]
https://listserv.rediris.es/cgi-bin/wa?SUBED1=OFER-TRABEC&A=1
===
SEGURIDAD: Los enlaces contenidos en este mensaje son seguros y protegidos con reescritura de URL_DEFENSE de Proofpoint
===

---Procedencia: 
 Institución:Institut de Recerca Biomèdica de Lleida (IRBLleida)
 Contacto correo-e:[log in para visualizar]
---
The Molecular Oncology group (http://bit.ly/molonco) at Institut de Recerca Biomèdica de Lleida (IRBLleida) is looking for a highly motivated researcher (R2) to apply for a postdoctoral research position funded by the ‘Sara Borrell” Program of the Spanish Government through the Ministry of Science, Innovation and Universities (Sara Borrell Call).

The group strategic lines in the oncology field are:
1)	Investigation of the molecular mechanisms underlying the initiation and progression of gastrointestinal (colorectal and gastric), head and neck and endometrial tumors, with the ultimate goal of improving the diagnosis and treatment of patients.
2)	Personalization of the chemotherapeutic treatment in patients with colorectal cancer. Our laboratory has been interested for long time in identifying new molecular biomarkers capable of predicting the response of patients with colorectal cancer to the treatment with small molecule chemotherapeutic agents.
3)	Study of drug-induced cellular senescence in colorectal cancer. The group studies in depth the senescence of colorectal tumors after the exposure to specific drugs, and the way to efficiently eliminate them to contribute to the improvement of oncological treatments.

For this position it is:

Required:
- Hold a PhD degree in biological or biomedical sciences obtained after the 1st of January 2021 (with the exceptions listed in the call),
- Strong publication record as first-author in indexed international journals in the first decile/quartile,

Valued:
- Participation as a co-author in additional publications,
- Research stays in national/international research centers/institutions,
- Participation in national/international conferences,
- Direction of master's or undergraduate students,
- Communication skills and ability to interact with a high level scientific environment,
- Fluency in English (spoken and written),
- Ability to work in a team, but also individually assuming responsibilities and meeting deadlines,
- Organizational, proactive and self-motivated attitude.

Offered:
- Full-time 3 years contract,
- Remuneration: 30.000€/year (2-year period) and 35.000€/year (1-year period) (gross annual salary),
- Skillful and social colleagues, a highly stimulating and dynamic scientific environment, state-of-the-art infrastructures, challenging tasks, wide range of responsibilities and unique professional career development opportunities.

Application Procedure:
All applications must be addressed by email to [log in para visualizar] and include:
- A complete CV,
- A motivation letter,
- Contact details for reference.
Please, indicate SB2025-RI in the subject.

The submission deadline will end on February 20th 2025 at 12h.

Selection process:
- Pre-selection: Will be based on CV, motivation letter and experience.
- Interviews: Short-listed candidates will be interviewed.

 ----------------
Información complementaria de la oferta:
The Institute:
IRBLleida acts as a cluster of all biomedical research carried out in Lleida and incorporates to two stakeholders that conduct health research and implement innovation policies:
. The University of Lleida (UdL) includes researchers from the Faculties of Medicine, Nursing and Physiotherapy.
· The Department of Health, includes researchers from Arnau de Vilanova University Hospital (HUAV), Santa María University Hospital (HUSM), Catalan Health Institute (ICS) and Lleida Primary Care and Community.
IRBLleida is a CERCA center, the biocluster supported and supervised by the Autonomous Government of Catalonia, and it is also accredited as a Centre of Excellence by Carlos III Health Institute (funded by Spanish Government).

We offer and promote a diverse and inclusive environment and welcome applicants regardless gender, nationality, ethnicity or religion. IRBLleida is awarded with the 'HR Excellence in Research' from the European Commission. This recognition reflects the commitment of IRBLleida recruitment and appraisal procedures in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers.

ATOM RSS1 RSS2